Cramer Rosenthal Mcglynn LLC Purchases 89,031 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Cramer Rosenthal Mcglynn LLC grew its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,706,225 shares of the company's stock after acquiring an additional 89,031 shares during the period. Elanco Animal Health accounts for 1.9% of Cramer Rosenthal Mcglynn LLC's portfolio, making the stock its 15th largest holding. Cramer Rosenthal Mcglynn LLC owned about 0.55% of Elanco Animal Health worth $32,772,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of ELAN. Steward Partners Investment Advisory LLC raised its stake in shares of Elanco Animal Health by 28.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after acquiring an additional 2,264 shares during the last quarter. DDD Partners LLC acquired a new position in Elanco Animal Health during the 4th quarter worth $5,974,000. Harbor Capital Advisors Inc. boosted its position in Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after buying an additional 209,734 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Elanco Animal Health by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock valued at $5,349,000 after buying an additional 45,795 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Up 3.9 %

Shares of NYSE ELAN traded up $0.35 during mid-day trading on Wednesday, reaching $9.24. 2,989,785 shares of the company's stock were exchanged, compared to its average volume of 4,905,451. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $10.15 and a 200 day simple moving average of $11.74. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.80. The firm has a market capitalization of $4.59 billion, a price-to-earnings ratio of 23.10, a PEG ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm posted $0.08 EPS. The business's quarterly revenue was down 1.4% compared to the same quarter last year. As a group, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Morgan Stanley reduced their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus dropped their price objective on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday, April 14th. Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Finally, UBS Group cut their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Elanco Animal Health has a consensus rating of "Hold" and a consensus target price of $14.67.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.89% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.